Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Capital Expenditures (2024 - 2025)

Prelude Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $20000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures fell 94.43% year-over-year to $20000.0; the TTM value through Dec 2025 reached $67000.0, up 570.0%, while the annual FY2025 figure was $67000.0, 570.0% up from the prior year.
  • Capital Expenditures for Q2 2025 was $20000.0 at Prelude Therapeutics, down from $47000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $359000.0 in Q2 2024 and bottomed at -$701000.0 in Q4 2024.